Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Rectal Diseases 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neoplasms 1Neoplasms by Site 1Neoplasms 1Kidney Neoplasms 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Gallbladder Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Colonic Diseases 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1

Interventions

lutetium Lu 177 dotatate 1guadecitabine 1copper dotatate CU-64 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Lutetium-177 1Lutetium 1Ipilimumab 1Fluorodeoxyglucose F18 1CTLA-4 Antigen 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraganglioma × guadecitabine × Gastrointestinal × Clear all
NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
9 enrolled 11 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡